Bladder cancer clinical trials

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 4, 2005, Pages 275-279

  Lerner, Seth P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder cancer; Chemoprevention; Chemotherapy; Clinical trials; Immunotherapy; Intravesical therapy

Indexed keywords

5 HEXYLAMINOLEVULINATE; ALPHA2B INTERFERON; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; BACTERIAL DNA; BCG VACCINE; BIOLOGICAL MARKER; CARBOPLATIN; CELECOXIB; CISPLATIN; DOXORUBICIN; EFLORNITHINE; EPIRUBICIN; ERLOTINIB; FENRETINIDE; FLUOROURACIL; FR 901228; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GREEN TEA EXTRACT; IRINOTECAN; IXABEPILONE; METHOTREXATE; MITOMYCIN C; NUCLEAR MATRIX PROTEIN; PACLITAXEL; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE;

ADJUVANT CHEMOTHERAPY; BACTERIAL CELL WALL; BLADDER CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESEARCH; CANCER SURGERY; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DNA MICROARRAY; DOSE RESPONSE; HUMAN; MYCOBACTERIUM; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; MULTICENTER STUDIES; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; URINARY BLADDER NEOPLASMS;

EID: 21844454175     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.05.005     Document Type: Review

References (9)

1. M.O. Hoque, J. Lee, S. Begum High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array Cancer Res 63 2003 5723 5726
2. R.J. Sylvester, W. Oosterlinck, A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer A meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190
3. M. Laufer, S. Ramalingam, M.P. Schoenberg Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder A phase I and pharmacokinetic study J Clin Oncol 21 2003 697 703
4. G. Dalbagni, P. Russo, J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198
5. M.A. O'Donnell, K. Lilli, C. Leopold Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer J Urol 172 2004 888 893
6. W.U. Shipley, D.S. Kaufman, W.J. Tester Overview of bladder cancer trials in the Radiation Therapy Oncology Group Cancer 97 Suppl 8 2003 2115 2119
7. L. Norton, R. Simon The Norton-Simon hypothesis revisited Cancer Treat Rep 70 1986 163 169
8. M.D. Sachs, M. Ramamurthy, H. Poel Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells Cancer Gene Ther 11 2004 477 486
9. Z. Latif, A.D. Watters, I. Dunn HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder A role for anti-HER2 therapy? Eur J Cancer 40 2004 56 63